About this market
UK private dermatology provision spans chemical peels, phototherapy, skin biopsies and lesion excision rather than skincare alone. Across all approved UK locations, Rare.Monitor records dermatology provision at 12,106 locations, linked to 4,180 distinct owner records, on figures read on 20 August 2026. Skin conditions such as eczema and rosacea are held as a separate classification and are not counted in that figure.
FAQ
Frequently asked questions
Questions answered from Rare.Monitor data, figures read 20 August 2026.
How many UK locations record private dermatology treatment?
Rare.Monitor records dermatology provision at 12,106 approved UK locations. The classification is detected from what each location publishes about its own treatments, so the count records private provision rather than measuring the whole market, and it does not include NHS dermatology services. Source: Rare.Monitor, figures read 20 August 2026.What counts as dermatology provision in Rare.Monitor data?
Dermatology provision in Rare.Monitor covers treatments a location offers, including chemical peels, microneedling, phototherapy, intense pulsed light, skin biopsies, lesion excision and topical or oral medication, recorded from each UK location's own published text. Skin conditions such as eczema and rosacea are held in a separate classification and are not counted in this hub's figures. Source: Rare.Monitor.How is UK private dermatology structured by ownership?
Rare.Monitor links the 12,106 approved UK locations recording dermatology provision to 4,180 distinct owner records. Rare.Monitor counts distinct owner records rather than how many locations each owner holds, so these figures do not show how concentrated ownership is or how many providers operate from a single site. Locations approved most recently have not yet been matched to an owner record, so 4,180 counts the owners matched so far rather than every owner behind these locations. Source: Rare.Monitor, figures read 20 August 2026.What does Rare.Monitor track in the dermatology segment?
Rare.Monitor tracks treatment classifications, brand mentions and ownership links across more than 230,000 reportable locations in the United Kingdom and Republic of Ireland (ROI). For dermatology that covers which skin treatments each UK location publishes, which product and treatment brands it names, and which organisation owns it. Records are built from what each location publishes, so figures are restated on each new market read. Source: Rare.Monitor, platform figures read 4 August 2026.Does Rare.Monitor cover NHS dermatology as well as private providers?
Rare.Monitor records private provision only, built from what each location publishes about its own treatments. The prescribing analysis on this page uses published NHS data rather than Rare.Monitor data, so its figures and the provider counts on this page are not counted on the same basis and are not comparable. Source: Rare.Monitor.
Methodology: Rare.Monitor is a private-market dataset, built on what each location publishes about its own treatments rather than on an official market survey, so a count records provision rather than measuring the whole market. Market figures on this page were read on 20 August 2026, in one read. Rare.Monitor records dermatology provision at 12,106 approved UK locations, linked to 4,180 distinct owner records over the same locations in the same read. Dermatology here means treatments a location offers, such as chemical peels, microneedling, phototherapy, intense pulsed light, skin biopsies, lesion excision and topical or oral medication. Skin conditions are held in a separate classification and are not counted in these figures. Locations in this cohort were approved into the dataset between February and August 2026. Rare.Monitor records private provision only. The NHS prescribing figures in the analyses linked below come from published NHS sources, not from Rare.Monitor, and the two are not counted on the same basis. Rare.Monitor counts distinct owner records rather than how many locations each owner holds, so they support no statement about how concentrated ownership is. Provider matching runs as a later stage, so locations approved most recently are not yet matched to an owner record, and the count covers the owners matched so far rather than every owner behind these locations. The classification is detected from website text rather than confirmed by a regulator, so a count carries some records the detection has placed wrongly. Most records have not yet had a full treatment re-scrape, so the count records the locations detected so far rather than every UK location offering these treatments. Classification passes for the cohort fall in a rolling nine to ten week window rather than on one fixed collection date. Platform-wide figures were read separately on 4 August 2026 and are not comparable with the market figures above. Figures in the linked analyses below come from earlier snapshots measured on their own bases, so they are not a trend series with the figures on this page. Source: Rare.Monitor.